Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 18/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085491 | 1.00 | PTGER4 (0.57) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754098 | 0.91 | PTGER4 (0.48) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754088 | 0.91 | PTGER4 (0.58) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754080 | 0.91 | PTGER4 (0.58) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754083 | 0.88 | PTGER4 (0.54) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754112 | 0.86 | PTGER4 (0.52) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754111 | 0.84 | PTGER4 (0.50) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754079 | 0.84 | PTGER4 (0.47) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754084 | 0.83 | PTGER4 (0.47) | PTGER4PTGER2PTGER1PTGER3 | |
| SCHEMBL30754103 | 0.82 | PTGER4 (0.47) | PTGER4PTGER2PTGER1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125347-A1 | l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260125347-A1 | l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4565565-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| EP-4565565-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654310-A | 1, 2-Substituted 3-oxo-pyrazolidine derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119654310-A | 1, 2-Substituted 3-oxo-pyrazolidine derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024028601-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028601-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125347-A1 | l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, OXER1 | PTGER4 1/4885PTGER2 4/4885PTGER1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.